BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33663520)

  • 21. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic value of DAPK1 hypermethylation in gliomas: A site-specific analysis.
    Li X; Pu J; Liu J; Chen Y; Li Y; Hou P; Shi B; Yang Q
    Pathol Res Pract; 2018 Jul; 214(7):940-948. PubMed ID: 29807777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 promoter methylation in human gliomas.
    Amatya VJ; Naumann U; Weller M; Ohgaki H
    Acta Neuropathol; 2005 Aug; 110(2):178-84. PubMed ID: 16025287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
    Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA
    Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion.
    Wang H; Wang Y; Bao Z; Zhang C; Liu Y; Cai J; Jiang C
    Oncol Rep; 2015 Sep; 34(3):1503-9. PubMed ID: 26165699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
    Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
    Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation.
    Monteiro-Reis S; Leça L; Almeida M; Antunes L; Monteiro P; Dias PC; Morais A; Oliveira J; Henrique R; Jerónimo C
    Eur J Cancer; 2014 Jan; 50(1):226-33. PubMed ID: 24100025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma.
    Lopci E; Riva M; Olivari L; Raneri F; Soffietti R; Piccardo A; Bizzi A; Navarria P; Ascolese AM; Rudà R; Fernandes B; Pessina F; Grimaldi M; Simonelli M; Rossi M; Alfieri T; Zucali PA; Scorsetti M; Bello L; Chiti A
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1155-1164. PubMed ID: 28110346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
    Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative DNA methylation analysis of selected genes in endometrial carcinogenesis.
    Chen YC; Tsao CM; Kuo CC; Yu MH; Lin YW; Yang CY; Li HJ; Yan MD; Wang TJ; Chou YC; Su HY
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):572-9. PubMed ID: 26522113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of TMEFF2 methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma.
    Chen E; Zheng F; Yuan X; Ye Y; Li X; Dai Y; Chen L
    Cancer Biomark; 2017; 19(2):207-212. PubMed ID: 28128743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. von Willebrand Factor Gene Expression in Primary Lower Grade Glioma: Mutually Co-Occurring Mutations in von Willebrand Factor, ATRX, and TP53.
    Lehrer S; Rheinstein PH; Green S; Rosenzweig KE
    Brain Tumor Res Treat; 2019 Apr; 7(1):33-38. PubMed ID: 31062529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
    Sipayya V; Sharma I; Sharma KC; Singh A
    J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.
    Shukla S; Pia Patric IR; Thinagararjan S; Srinivasan S; Mondal B; Hegde AS; Chandramouli BA; Santosh V; Arivazhagan A; Somasundaram K
    Cancer Res; 2013 Nov; 73(22):6563-73. PubMed ID: 24078801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
    Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
    Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
    [No Abstract]   [Full Text] [Related]  

  • 39. SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.
    Li X; Zhang W; Song J; Zhang X; Ran L; He Y
    Clin Epigenetics; 2019 Jul; 11(1):99. PubMed ID: 31288850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promoter hypermethylation-mediated inactivation of LRRC4 in gliomas.
    Zhang Z; Li D; Wu M; Xiang B; Wang L; Zhou M; Chen P; Li X; Shen S; Li G
    BMC Mol Biol; 2008 Nov; 9():99. PubMed ID: 18976507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.